These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32582526)

  • 1. Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
    Usuda K; Niida Y; Iwai S; Funasaki A; Sekimura A; Motono N; Yamada S; Uramoto H
    Front Oncol; 2020; 10():689. PubMed ID: 32582526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression.
    Uenami T; Ishijima M; Kanazu M; Kurebe H; Edahiro R; Nishida K; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Ann Transl Med; 2018 Nov; 6(22):444. PubMed ID: 30596074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
    Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
    Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: anaplastic lymphoma kinase (
    Shigeta N; Murakami S; Yokose T; Miyagi Y; Saito H
    Front Oncol; 2023; 13():1110638. PubMed ID: 37114121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability
    Jin Z; Yoon HH
    J Gastrointest Oncol; 2016 Oct; 7(5):771-788. PubMed ID: 27747091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1.
    Kim SR; Chun SH; Kim JH; Kim SY; Lee BI; Jung CK; Kang JH
    Korean J Clin Oncol; 2020 Jun; 16(1):57-62. PubMed ID: 36945301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.
    Eso Y; Seno H
    Therap Adv Gastroenterol; 2020; 13():1756284820948773. PubMed ID: 32913444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.